These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30070367)

  • 1. A Case of Immune-Mediated Liver Injury Induced by Olaparib.
    Tufoni M; Serena Ricci C; Zaccherini G
    Hepatology; 2018 Nov; 68(5):2039-2041. PubMed ID: 30070367
    [No Abstract]   [Full Text] [Related]  

  • 2. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer.
    Shammo JM; Usha L; Richardson KJ; Elliott E; Dewdney S; Venugopal P; Cobleigh M; Kuzel TM
    J Oncol Pract; 2019 Jul; 15(7):405-407. PubMed ID: 31199709
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychotropic Drugs and Liver Toxicity.
    Gómez-Lumbreras A; Marcos-Fosch C; Aguilera C
    Am J Ther; 2018; 25(5):e601-e602. PubMed ID: 30188878
    [No Abstract]   [Full Text] [Related]  

  • 4. Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus.
    Quartuccio L; Maset M; Soardo G; Avellini C; De Vita S
    J Clin Rheumatol; 2014 Sep; 20(6):349-51. PubMed ID: 25160028
    [No Abstract]   [Full Text] [Related]  

  • 5. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous arteritis during olaparib treatment for ovarian cancer.
    Iinuma S; Takahashi C; Negishi H; Ishida-Yamamoto A
    J Dermatol; 2021 Mar; 48(3):e140-e141. PubMed ID: 33404077
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
    Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report.
    Abenavoli L; Milic N; Beaugrand M
    Ann Hepatol; 2013; 12(1):152-5. PubMed ID: 23293208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
    Ferrero D; Pogliani EM; Rege-Cambrin G; Fava C; Mattioli G; Dellacasa C; Campa E; Perfetti P; Fumagalli M; Boccadoro M
    Haematologica; 2006 Jun; 91(6 Suppl):ECR27. PubMed ID: 16785130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    Ziemer M; Koukoulioti E; Beyer S; Simon JC; Berg T
    J Hepatol; 2017 Mar; 66(3):657-659. PubMed ID: 27908801
    [No Abstract]   [Full Text] [Related]  

  • 11. [Toxic hepatitis caused by ketoconazole (Nizoral)].
    Boëtius G; Peeters JP; Peters JH
    Ned Tijdschr Geneeskd; 1983 Feb; 127(8):341-3. PubMed ID: 6300702
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety evaluation of olaparib for treating ovarian cancer.
    Lheureux S; Bowering V; Karakasis K; Oza AM
    Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R; Gourley C
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
    Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L
    Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib for the treatment of ovarian cancer.
    Bornstein E; Jimeno A
    Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
    Roviello G; Milani M; Gobbi A; Dester M; Cappelletti MR; Allevi G; Aguggini S; Ravelli A; Gussago F; Cocconi A; Zanotti L; Senti C; Strina C; Bottini A; Generali D
    Future Oncol; 2016 Oct; 12(19):2189-93. PubMed ID: 27324108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.